Operating Lease, Right-of-Use Asset in USD of NeuBase Therapeutics, Inc. from Q3 2020 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
NeuBase Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and change rate from Q3 2020 to Q3 2023.
  • NeuBase Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2023 was $5,064,184, a 9.81% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

NeuBase Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $5,064,184 -$550,514 -9.8% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $5,181,436 -$569,166 -9.9% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $5,296,545 -$587,411 -10% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $5,409,574 -$432,122 -7.4% 31 Dec 2022 10-Q 09 Nov 2023 2023 Q3
Q3 2022 $5,614,698 -$330,597 -5.6% 30 Sep 2022 10-QT 05 Jun 2023 2022 Q1
Q2 2022 $5,750,602 -$297,748 -4.9% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q3
Q1 2022 $5,883,956 31 Mar 2022 10-Q 12 May 2022 2022 Q2
Q4 2021 $5,841,696 31 Dec 2021 10-Q 11 Feb 2022 2022 Q1
Q3 2021 $5,945,295 +$5,945,295 30 Sep 2021 10-K 21 Dec 2022 2022 FY
Q2 2021 $6,048,350 30 Jun 2021 10-Q 13 Aug 2021 2021 Q3
Q3 2020 $0 30 Sep 2020 10-K 23 Dec 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.